Log In
Print
BCIQ
Print
Print this Print this
 

Aromasin, exemestane

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionIrreversible aromatase inhibitor
Molecular Target Aromatase
Mechanism of ActionAromatase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationBreast cancer
Indication DetailsAdjuvant treat hormone positive breast cancer in postmenopausal women; Prevent breast cancer; Reduce the risk of estrogen receptor-positive cancer in high-risk women; Treat advanced breast cancer; Treat breast cancer in postmenopausal women with advanced or recurrent breast cancer; Treat early, hormone-sensitive breast cancer in postmenopausal women; Treat estrogen receptor-positive early breast cancer following 2-3 years of initial adjuvant tamoxifen therapy in postmenopausal women
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today